Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$275,198
+$29,523 QoQ
Shares Held
38,870
+26.9% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#70
of 164 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026AQR CAPITAL MANAGEMENT LLC holds $6,352,612,055 across 16 Drug Manufacturers - General names. GRFS ranks #16 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
27,357,486 | $1,576,338,337 | |
| 2 | LLY |
ELI LILLY & Co
|
1,035,605 | $1,242,135,802 | |
| 3 | MRK |
Merck & Co., Inc.
|
8,134,262 | $1,045,252,665 | |
| 4 | JNJ |
Johnson & Johnson
|
2,907,803 | $738,494,723 | |
| 5 | ABBV |
AbbVie Inc.
|
2,015,238 | $507,114,486 | |
| 6 | PFE |
Pfizer Inc
|
18,557,891 | $446,874,011 | |
| 7 | BIIB |
Biogen Inc.
|
1,936,859 | $418,477,751 | |
| 8 | AMGN |
Amgen Inc
|
300,007 | $108,638,532 |
All Filings in GRFS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $275,198 | 38,870 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $245,675 | 30,633 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $195,714 | 20,932 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $214,249 | 21,511 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $156,979 | 17,365 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $98,942 | 13,916 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $129,664 | 17,428 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $164,519 | 18,527 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $89,015 | 14,107 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||